What is the 13F Pro Quality Score for GMED?

13F Pro ranks GLOBUS MEDICAL INC (GMED) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GMED's current score at https://13fpro.ai/research/GMED (free sign-up required for the full ranking).

Where does 13F Pro source GMED data?

All GLOBUS MEDICAL INC fundamentals and ownership data come directly from SEC EDGAR. GLOBUS MEDICAL INC files with the SEC under CIK 1237831. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GMED in?

GLOBUS MEDICAL INC (GMED) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GMED research updated on 13F Pro?

GMED's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GLOBUS MEDICAL INC(GMED)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1237831 GMED stock profile & AI dashboard →

13F Pro Quality Score

77.6/100

Rank #78 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.4/100

Profitability

86.2/100

Balance Sheet

86.2/100

Earnings Quality

94.1/100

Free Cash Flow

77.0/100

Institutional Flow

14.3/100

Revenue Scale

69.1/100

Dilution Risk

44.2/100

GMED Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GLOBUS MEDICAL INC (GMED), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMED at 77.6/100 on a 32-signal composite quality model, placing it at rank #78 of 2,879 stocks — the top 5% of the AI-ranked universe. GMED scores in the top quartile across earnings quality (94.1), revenue growth (89.4), profitability (86.2). Areas of concern include institutional flow (14.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 44.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GLOBUS MEDICAL INC reports quarterly revenue of $759.9M, net income of $124.3M, an operating margin of 19.8%. Top institutional holders of GMED by reported 13-F value include BlackRock,, JANUS HENDERSON GROUP PLC, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GMED trades on the NYSE exchange and files with the SEC under CIK 1237831. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLOBUS MEDICAL INC directly from SEC EDGAR. GLOBUS MEDICAL INC's 13F Pro composite quality score has ranged between 53 and 82 since 2021, currently 77.6 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about GLOBUS MEDICAL INC

Quirks, history, and lore behind GMED — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-cap · listed on NYSE · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with a product portfolio spanning hundreds of implant systems sold to hospitals and surgical centers worldwide.
3
The History
Founded in 2003 by a surgeon-entrepreneur who saw a gap in the market for musculoskeletal implants, the company went from startup to NYSE-listed in under a decade.
4
The Secret
It designs nearly all of its products in-house, giving it unusually tight control over both innovation and margins compared with larger orthopedic rivals.
5
The Lore
The company made a big splash by acquiring NuVasive, roughly doubling its scale and making it one of the larger pure-play spine implant companies on the market.
6
The Giveaway
If a surgeon is fusing vertebrae, there's a good chance the hardware came from this spine-focused implant maker whose name evokes a very well-traveled doctor.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$759.9M

Net Income

Q1 2026

$124.3M

Free Cash Flow

Q1 2026

$162.7M

Operating Margin

Q1 2026

19.8%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+87.4% YoY

$2.94BFY 2025

FY20 $789.0MFY22 $1.02BFY23 $1.57BFY25 $2.94B

Net Income

+337.7% YoY

$537.9MFY 2025

FY20 $102.3MFY22 $190.2MFY23 $122.9MFY25 $537.9M

Operating Income

+260.4% YoY

$479.8MFY 2025

FY20 $111.4MFY22 $228.0MFY23 $133.1MFY25 $479.8M

EPS (Diluted)

+266.4% YoY

$3.92FY 2025

FY20 $1.01FY22 $1.85FY23 $1.07FY25 $3.92

Total Assets

+4.3% YoY

$5.30BFY 2025

FY20 $1.68BFY22 $2.08BFY23 $5.09BFY25 $5.30B

Op. Cash Flow

+209.4% YoY

$753.4MFY 2025

FY20 $198.8MFY22 $178.5MFY23 $243.5MFY25 $753.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2020	FY 2017	FY 2016
Revenue	$2.94B +87.4%	$1.57B +53.3%	$1.02B +29.6%	$789.0M +24.1%	$636.0M +12.8%	$564.0M
Net Income	$537.9M +337.7%	$122.9M -35.4%	$190.2M +85.9%	$102.3M -4.7%	$107.3M +2.9%	$104.3M
Operating Income	$479.8M +260.4%	$133.1M -41.6%	$228.0M +104.6%	$111.4M -31.1%	$161.8M +5.0%	$154.1M
EPS (Diluted)	$3.92 +266.4%	$1.07 -42.2%	$1.85 +83.2%	$1.01 -8.2%	$1.10 +1.9%	$1.08
Total Assets	$5.30B +4.3%	$5.09B +145.0%	$2.08B +23.6%	$1.68B +55.7%	$1.08B +16.3%	$927.6M
Operating Cash Flow	$753.4M +209.4%	$243.5M +36.4%	$178.5M -10.2%	$198.8M +25.0%	$159.1M +7.6%	$147.8M

Get alerted when GMED's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GLOBUS MEDICAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GMED

BlackRock, Inc.
$904.5M10,497,414 sh
JANUS HENDERSON GROUP PLC
$656.8M7,623,095 sh
VANGUARD CAPITAL MANAGEMENT LLC
$433.6M5,032,732 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$420.4M4,879,459 sh
Invesco Ltd.
$371.9M4,316,654 sh
STATE STREET CORP
$309.3M3,590,372 sh
Sculptor Capital LP
$263.5M3,058,000 sh
BANK OF MONTREAL /CAN/
$198.8M2,307,181 sh
GEODE CAPITAL MANAGEMENT, LLC
$182.0M2,112,124 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$173.2M2,009,763 sh

Fund	Value	Shares
BlackRock, Inc.	$904.5M	10,497,414
JANUS HENDERSON GROUP PLC	$656.8M	7,623,095
VANGUARD CAPITAL MANAGEMENT LLC	$433.6M	5,032,732
VANGUARD PORTFOLIO MANAGEMENT LLC	$420.4M	4,879,459
Invesco Ltd.	$371.9M	4,316,654
STATE STREET CORP	$309.3M	3,590,372
Sculptor Capital LP	$263.5M	3,058,000
BANK OF MONTREAL /CAN/	$198.8M	2,307,181
GEODE CAPITAL MANAGEMENT, LLC	$182.0M	2,112,124
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$173.2M	2,009,763

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GMED on your watchlist

Track score changes the day GLOBUS MEDICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GMED a good stock to buy?

13F Pro's AI-powered analysis of GLOBUS MEDICAL INC (GMED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GMED are available on the GMED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GMED?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GMED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GLOBUS MEDICAL INC's investment landscape.